This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 1 for:    TAK-438/CPH-010
Previous Study | Return to List | Next Study

Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of Vonoprazan (TAK-438)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Takeda
ClinicalTrials.gov Identifier:
NCT02037477
First received: January 14, 2014
Last updated: August 22, 2016
Last verified: August 2016
  Purpose
The purpose of this study is to investigate the acid-inhibitory effect of multiple oral doses of Vonoprazan (TAK-438) and the relative effect of vonoprazan versus two controls (esomeprazole and rabeprazole sodium) in healthy Japanese adult male participants with the CYP2C19 extensive metabolizer (EM) genotype.

Condition Intervention Phase
Healthy Volunteers Drug: Vonoprazan Drug: Esomeprazole Drug: Rabeprazole sodium Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 3 Open-Label Crossover Pharmacodynamic Study to Evaluate the Acid-inhibitory Effect of TAK-438 20 mg With Esomeprazole 20 mg or Rabeprazole Sodium 10 mg in Healthy Adult Male Subjects

Resource links provided by NLM:


Further study details as provided by Takeda:

Primary Outcome Measures:
  • Intragastric pH Time Course Over 24 Hours [ Time Frame: At baseline (Day -2 to Day -1), administration period (Days 1 to Day 2 and Days 7 to Day 8) ]
    Intragastric pH was measured continuously for 24 hours (hr) by pH monitor. pH holding time ratio (HTR) is the percentage of time a pH is maintained at a particular level. For example, pH 4 HTR is the percentage of time the pH = 4.


Secondary Outcome Measures:
  • Frequency of Adverse Events [ Time Frame: 31 days ]
    The frequency of adverse events by type, seriousness, time to onset. Adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug to the last dose of study drug.

  • Number of Participants With Abnormal Changes From Baseline in Vital Signs [ Time Frame: At screening, baseline (Day -3, Day -2, Day -1), administration period (Days 1, Day 2, Day 7, Day 8), and post-test (Day 28) ]
    Vital signs included body temperature (oral or tympanic measurement), sitting blood pressure (after the participant has rested for at least 5 minutes), and pulse (bpm).

  • Number of Participants With Abnormal 12-lead Electrocardiogram (at Rest) Findings [ Time Frame: At Screening, baseline (Day -3), administration period (Day 8), and post-test (Day 28) ]
  • Number of Participants With Markedly Abnormal Laboratory Values [ Time Frame: At Screening, baseline (Day -3), administration period (Day 1, Day 8), and post-test (Day 28) ]
    The number of participants with markedly abnormal laboratory values for Chemistry, Hematology and Urinalysis during the study is reported.


Enrollment: 20
Study Start Date: January 2014
Study Completion Date: March 2014
Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Sequence A (Cohort 1): Vonoprazan + Esomeprazole
Vonoprazan (TAK-438) 20 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then esomeprazole 20 mg, orally, once daily for 7 days.
Drug: Vonoprazan
Vonoprazan tablets
Other Names:
  • TAK-438
  • Takecab®
Drug: Esomeprazole
Esomeprazole capsules
Other Name: Nexium (esomeprazole)
Experimental: Sequence B (Cohort 1): Esomeprazole + Vonoprazan
Esomeprazole 20 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then vonoprazan 20 mg, orally, once daily for 7 days.
Drug: Vonoprazan
Vonoprazan tablets
Other Names:
  • TAK-438
  • Takecab®
Drug: Esomeprazole
Esomeprazole capsules
Other Name: Nexium (esomeprazole)
Experimental: Sequence C (Cohort 2): Vonoprazan + Rabeprazole Sodium
Vonoprazan 20 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then Rabeprazole sodium 10 mg, orally, once daily for 7 days.
Drug: Vonoprazan
Vonoprazan tablets
Other Names:
  • TAK-438
  • Takecab®
Drug: Rabeprazole sodium
Rabeprazole sodium tablets
Other Name: Pariet (rabeprazole)
Experimental: Sequence D (Cohort 2): Rabeprazole Sodium + Vonoprazan
Rabeprazole sodium 10 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then vonoprazan 20 mg, orally, once daily for 7 days.
Drug: Vonoprazan
Vonoprazan tablets
Other Names:
  • TAK-438
  • Takecab®
Drug: Rabeprazole sodium
Rabeprazole sodium tablets
Other Name: Pariet (rabeprazole)

Detailed Description:

This is a Phase 3 open-label crossover study to evaluate the acid-inhibitory effect following 7 days multiple doses of vonoprazan (20 mg per dose) and esomeprazole (20 mg per dose) (Cohort 1) or vonoprazan (20 mg per dose) and rabeprazole sodium (10 mg per dose) (Cohort 2) in healthy Japanese adult male participants (CYP2C19 genotype: EM). There will be a total of 20 participants, 5 per group for both Cohorts 1 and 2. At least 2 participants each with the homo EM (*1/*1) or hetero EM (*1/*2, *1/*3) CYP2C19 genotype will be enrolled among the 5 participants per group.

The drug being tested in this study is called vonoprazan. This study will look at the acid inhibitory effect following 7 days multiple doses of vonoprazan and esomeprazole (Cohort 1) or vonoprazan and rabeprazole sodium (Cohort 2) in healthy Japanese adult male participants with the CYP2C19 EM genotype.

The study will enroll a total of 20 participants, 5 per group for both Cohorts. At least 2 participants each with the homo EM (*1/*1) or hetero EM (*1/*2, *1/*3) CYP2C19 genotype will be enrolled among the 5 participants per group.

  • Group A, Cohort 1: vonoprazan (20 mg per dose for 7 days) followed by esomeprazole (20 mg per dose for 7 days)
  • Group B, Cohort 1: esomeprazole (20 mg per dose for 7 days) followed by TAK-438 (20 mg per dose for 7 days)
  • Group C, Cohort 2: vonoprazan (20 mg per dose for 7 days) followed by rabeprazole sodium (10 mg per dose for 7 days)
  • Group D, Cohort 2: rabeprazole sodium (10 mg per dose for 7 days) followed by vonoprazan (20 mg per dose for 7 days).

All participants will be asked to take Study Medication at the same time each day throughout the study. This single center trial will be conducted in Japan. The overall time to participate in this study is 31 days.

  Eligibility

Ages Eligible for Study:   20 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Is a healthy Japanese adult male volunteer.
  2. Is aged 20 to 45 years, inclusive, at the time of informed consent.
  3. Has been confirmed at CYP2C19 genotyping as an Extensive Metabolizer [EM (*1/*1,*1/*2,*1/*3)].
  4. Capable of understanding and complying with the protocol requirements.
  5. The participant signs and dates a written informed consent form prior to the initiation of any study procedures.
  6. Weighs 50 kg or more and has body mass index (BMI) of 18.5 or more and less than 25.0 kg/m^2 at Screening or admission (Day -3).
  7. H. pylori-negative at Screening.

Exclusion Criteria:

  1. Has undergone resection of the upper gastrointestinal tract or vagotomy.
  2. Was determined to have hypoacidity or anacidity.
  3. Has a present or past history of acid-related disease (reflux esophagitis, gastric ulcer, duodenal ulcer, non-erosive gastroesophageal reflux, Barrett's esophagus, Zollinger-Ellison syndrome, etc.).
  4. Has undergone eradication of H. pylori within 6 months prior to the start of the study drug administration.
  5. Has uncontrolled, clinically significant neurologic, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, or endocrine disease or other abnormalities which may impact the ability of the subject to participate or potentially confound the study results.
  6. Has a known hypersensitivities or allergies to drugs or food.
  7. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 5 years prior to the start of the study drug administration.
  8. Has poor peripheral venous access.
  9. Had 200 mL or more of whole blood drawn within 4 weeks (28 days) prior to the start of the study drug administration or 400 mL or more of whole blood drawn within 12 weeks (84 days) prior to the start of the study drug administration.
  10. Had a total volume of 800 mL or more of whole blood drawn within 52 weeks (364 days) prior to the start of the study drug administration.
  11. Has undergone blood component draw within 2 weeks (14 days) prior to the start of the study drug administration.
  12. Requires treatment with any of the excluded medications specified in the study or requires nutrition with any vitamin supplements or foods prohibited in the study.
  13. Has received study medication within 16 weeks (112 days) prior to the start of the study drug administration.
  14. Has received vonoprazan (TAK-438) in the past.
  15. Has a history of cancer.
  16. Has a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody/antigen or serological reaction for syphilis at Screening.
  17. Has a Screening or admission (Day -3) abnormal clinically significant electrocardiogram (ECG).
  18. Has abnormal Screening or admission (Day -3) laboratory values that suggest a clinically significant underlying disease or subject with the following lab abnormalities: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > twice the upper limit of the normal range.
  19. Is an immediate family member, study site employee, or in a dependent relationship with a study site employee who is involved in the conduct of this study (e.g., spouse, parent, child, sibling) or may consent under duress.
  20. Participant who, in the opinion of the investigator or sub-investigator, is unlikely to comply with the protocol or is unsuitable for any other reasons.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02037477

Locations
Japan
Fukuoka-shi, Fukuoka, Japan
Sponsors and Collaborators
Takeda
Investigators
Study Director: General Manager Takeda
  More Information

Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT02037477     History of Changes
Other Study ID Numbers: TAK-438/CPH-010
U1111-1152-3926 ( Registry Identifier: UTN (WHO) )
JapicCTI-142411 ( Registry Identifier: JapicCTI )
JapicCTI-R150821 ( Registry Identifier: JapicCTI )
Study First Received: January 14, 2014
Results First Received: March 27, 2015
Last Updated: August 22, 2016

Additional relevant MeSH terms:
Esomeprazole
Rabeprazole
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 18, 2017